News

Irish Medical Times12h
Two new indications of Tremfya (guselkumab) approved for the treatment of Inflammatory Bowel Disease
Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...
Clinical Trials Arena on MSN18h
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...
Seeking Alpha1mon
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
1 Patients treated with TREMFYA ® sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history. "People living with ulcerative colitis seek ...
KXAN1mon
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
"These results highlight the potential of TREMFYA to redefine ulcerative colitis care with a fully subcutaneous induction and maintenance regimen that offers a convenient option with meaningful ...
KXAN1mon
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
today announced new data from the TREMFYA ® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among ...
Morningstar1mon
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
"Data from the ASTRO study demonstrate that subcutaneous induction treatment with TREMFYA provides clinically meaningful remission in patients with ulcerative colitis, similar to the effects seen ...